Loading…
The potential therapeutic effects of ergothioneine in pre-eclampsia
Ergothioneine (ERG), is a water-soluble amino acid that is derived entirely from dietary sources. It has received much attention as a therapeutic agent due to its anti-oxidant properties, and there are claims of preferential accumulation within high oxidative stress organs. Pre-eclampsia, a conditio...
Saved in:
Published in: | Free radical biology & medicine 2018-03, Vol.117, p.145-157 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3 |
container_end_page | 157 |
container_issue | |
container_start_page | 145 |
container_title | Free radical biology & medicine |
container_volume | 117 |
creator | Kerley, Robert N. McCarthy, Cathal Kell, Douglas B. Kenny, Louise C. |
description | Ergothioneine (ERG), is a water-soluble amino acid that is derived entirely from dietary sources. It has received much attention as a therapeutic agent due to its anti-oxidant properties, and there are claims of preferential accumulation within high oxidative stress organs. Pre-eclampsia, a condition accompanied by increased oxidative stress, is one of the leading causes of maternal morbidity and mortality. Despite intense research efforts, its aetiologies remain somewhat unclear and there are still no effective treatment options. Clinical trials of the anti-oxidants vitamin C and vitamin E have proven largely ineffective with little improvement in clinical outcome or even a negative response. This could be explained in part by their inability to permeate the plasma and mitochondrial membranes and scavenge mitochondria-derived superoxide species, and for the former by the fact that it is actually a pro-oxidant in the presence of unliganded iron. ERG accumulates within tissues through the action of a specific organic cation transporter, SLC22A4 (previously referred to as OCTN1), which is possibly also expressed in mammalian mitochondria. Mitochondrial dysfunction has been implicated in a variety of vascular diseases including pre-eclampsia. This review discusses the use of ERG as a possibly mitochondrial-targeted anti-oxidant, focusing on its physical properties, potential mechanisms of action, safety profile and administration in relation to pregnancies complicated by pre-eclampsia.
[Display omitted] |
doi_str_mv | 10.1016/j.freeradbiomed.2017.12.030 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1982841573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0891584917312820</els_id><sourcerecordid>1982841573</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3</originalsourceid><addsrcrecordid>eNqNkLtOwzAUhi0EoqXwCigSC0vCsXOxLSZUlYuExAKzZTvH1FUaBztF4u1JVRjYmM5w_ov-j5ArCgUF2txsChcRo26ND1tsCwaUF5QVUMIRmVPBy7yqZXNM5iAkzWtRyRk5S2kDAFVdilMyY5KJitJmTpava8yGMGI_et1l43oKHnA3epuhc2jHlAWXYXwP49qHHn2Pme-zIWKOttPbIXl9Tk6c7hJe_NwFebtfvS4f8-eXh6fl3XNuq7IZ88oxC4bVhnMGxhkroQFT15LrUoqqBGcY49Ra3kouEDTnrW1cKzSroTWmXJDrQ-4Qw8cO06i2PlnsOt1j2CVFpdjPqnk5SW8PUhtDShGdGqLf6vilKKg9RbVRfyiqPUVFmZooTu7Ln6Kd2f9-vb_YJsHqIMBp7qfHqJL12FtsfZyYqTb4fxV9A88ni2k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1982841573</pqid></control><display><type>article</type><title>The potential therapeutic effects of ergothioneine in pre-eclampsia</title><source>ScienceDirect Journals</source><creator>Kerley, Robert N. ; McCarthy, Cathal ; Kell, Douglas B. ; Kenny, Louise C.</creator><creatorcontrib>Kerley, Robert N. ; McCarthy, Cathal ; Kell, Douglas B. ; Kenny, Louise C.</creatorcontrib><description>Ergothioneine (ERG), is a water-soluble amino acid that is derived entirely from dietary sources. It has received much attention as a therapeutic agent due to its anti-oxidant properties, and there are claims of preferential accumulation within high oxidative stress organs. Pre-eclampsia, a condition accompanied by increased oxidative stress, is one of the leading causes of maternal morbidity and mortality. Despite intense research efforts, its aetiologies remain somewhat unclear and there are still no effective treatment options. Clinical trials of the anti-oxidants vitamin C and vitamin E have proven largely ineffective with little improvement in clinical outcome or even a negative response. This could be explained in part by their inability to permeate the plasma and mitochondrial membranes and scavenge mitochondria-derived superoxide species, and for the former by the fact that it is actually a pro-oxidant in the presence of unliganded iron. ERG accumulates within tissues through the action of a specific organic cation transporter, SLC22A4 (previously referred to as OCTN1), which is possibly also expressed in mammalian mitochondria. Mitochondrial dysfunction has been implicated in a variety of vascular diseases including pre-eclampsia. This review discusses the use of ERG as a possibly mitochondrial-targeted anti-oxidant, focusing on its physical properties, potential mechanisms of action, safety profile and administration in relation to pregnancies complicated by pre-eclampsia.
[Display omitted]</description><identifier>ISSN: 0891-5849</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2017.12.030</identifier><identifier>PMID: 29284116</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antioxidants - pharmacology ; Ergothioneine ; Ergothioneine - pharmacology ; Female ; Humans ; Oxidative stress ; Oxidative Stress - drug effects ; Pre-eclampsia ; Pre-Eclampsia - metabolism ; Pre-Eclampsia - physiopathology ; Pregnancy</subject><ispartof>Free radical biology & medicine, 2018-03, Vol.117, p.145-157</ispartof><rights>2018 The Authors</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3</citedby><cites>FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29284116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kerley, Robert N.</creatorcontrib><creatorcontrib>McCarthy, Cathal</creatorcontrib><creatorcontrib>Kell, Douglas B.</creatorcontrib><creatorcontrib>Kenny, Louise C.</creatorcontrib><title>The potential therapeutic effects of ergothioneine in pre-eclampsia</title><title>Free radical biology & medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Ergothioneine (ERG), is a water-soluble amino acid that is derived entirely from dietary sources. It has received much attention as a therapeutic agent due to its anti-oxidant properties, and there are claims of preferential accumulation within high oxidative stress organs. Pre-eclampsia, a condition accompanied by increased oxidative stress, is one of the leading causes of maternal morbidity and mortality. Despite intense research efforts, its aetiologies remain somewhat unclear and there are still no effective treatment options. Clinical trials of the anti-oxidants vitamin C and vitamin E have proven largely ineffective with little improvement in clinical outcome or even a negative response. This could be explained in part by their inability to permeate the plasma and mitochondrial membranes and scavenge mitochondria-derived superoxide species, and for the former by the fact that it is actually a pro-oxidant in the presence of unliganded iron. ERG accumulates within tissues through the action of a specific organic cation transporter, SLC22A4 (previously referred to as OCTN1), which is possibly also expressed in mammalian mitochondria. Mitochondrial dysfunction has been implicated in a variety of vascular diseases including pre-eclampsia. This review discusses the use of ERG as a possibly mitochondrial-targeted anti-oxidant, focusing on its physical properties, potential mechanisms of action, safety profile and administration in relation to pregnancies complicated by pre-eclampsia.
[Display omitted]</description><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Ergothioneine</subject><subject>Ergothioneine - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Pre-eclampsia</subject><subject>Pre-Eclampsia - metabolism</subject><subject>Pre-Eclampsia - physiopathology</subject><subject>Pregnancy</subject><issn>0891-5849</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkLtOwzAUhi0EoqXwCigSC0vCsXOxLSZUlYuExAKzZTvH1FUaBztF4u1JVRjYmM5w_ov-j5ArCgUF2txsChcRo26ND1tsCwaUF5QVUMIRmVPBy7yqZXNM5iAkzWtRyRk5S2kDAFVdilMyY5KJitJmTpava8yGMGI_et1l43oKHnA3epuhc2jHlAWXYXwP49qHHn2Pme-zIWKOttPbIXl9Tk6c7hJe_NwFebtfvS4f8-eXh6fl3XNuq7IZ88oxC4bVhnMGxhkroQFT15LrUoqqBGcY49Ra3kouEDTnrW1cKzSroTWmXJDrQ-4Qw8cO06i2PlnsOt1j2CVFpdjPqnk5SW8PUhtDShGdGqLf6vilKKg9RbVRfyiqPUVFmZooTu7Ln6Kd2f9-vb_YJsHqIMBp7qfHqJL12FtsfZyYqTb4fxV9A88ni2k</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Kerley, Robert N.</creator><creator>McCarthy, Cathal</creator><creator>Kell, Douglas B.</creator><creator>Kenny, Louise C.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201803</creationdate><title>The potential therapeutic effects of ergothioneine in pre-eclampsia</title><author>Kerley, Robert N. ; McCarthy, Cathal ; Kell, Douglas B. ; Kenny, Louise C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Ergothioneine</topic><topic>Ergothioneine - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Pre-eclampsia</topic><topic>Pre-Eclampsia - metabolism</topic><topic>Pre-Eclampsia - physiopathology</topic><topic>Pregnancy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kerley, Robert N.</creatorcontrib><creatorcontrib>McCarthy, Cathal</creatorcontrib><creatorcontrib>Kell, Douglas B.</creatorcontrib><creatorcontrib>Kenny, Louise C.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Free radical biology & medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kerley, Robert N.</au><au>McCarthy, Cathal</au><au>Kell, Douglas B.</au><au>Kenny, Louise C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential therapeutic effects of ergothioneine in pre-eclampsia</atitle><jtitle>Free radical biology & medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2018-03</date><risdate>2018</risdate><volume>117</volume><spage>145</spage><epage>157</epage><pages>145-157</pages><issn>0891-5849</issn><eissn>1873-4596</eissn><abstract>Ergothioneine (ERG), is a water-soluble amino acid that is derived entirely from dietary sources. It has received much attention as a therapeutic agent due to its anti-oxidant properties, and there are claims of preferential accumulation within high oxidative stress organs. Pre-eclampsia, a condition accompanied by increased oxidative stress, is one of the leading causes of maternal morbidity and mortality. Despite intense research efforts, its aetiologies remain somewhat unclear and there are still no effective treatment options. Clinical trials of the anti-oxidants vitamin C and vitamin E have proven largely ineffective with little improvement in clinical outcome or even a negative response. This could be explained in part by their inability to permeate the plasma and mitochondrial membranes and scavenge mitochondria-derived superoxide species, and for the former by the fact that it is actually a pro-oxidant in the presence of unliganded iron. ERG accumulates within tissues through the action of a specific organic cation transporter, SLC22A4 (previously referred to as OCTN1), which is possibly also expressed in mammalian mitochondria. Mitochondrial dysfunction has been implicated in a variety of vascular diseases including pre-eclampsia. This review discusses the use of ERG as a possibly mitochondrial-targeted anti-oxidant, focusing on its physical properties, potential mechanisms of action, safety profile and administration in relation to pregnancies complicated by pre-eclampsia.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29284116</pmid><doi>10.1016/j.freeradbiomed.2017.12.030</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0891-5849 |
ispartof | Free radical biology & medicine, 2018-03, Vol.117, p.145-157 |
issn | 0891-5849 1873-4596 |
language | eng |
recordid | cdi_proquest_miscellaneous_1982841573 |
source | ScienceDirect Journals |
subjects | Animals Antioxidants - pharmacology Ergothioneine Ergothioneine - pharmacology Female Humans Oxidative stress Oxidative Stress - drug effects Pre-eclampsia Pre-Eclampsia - metabolism Pre-Eclampsia - physiopathology Pregnancy |
title | The potential therapeutic effects of ergothioneine in pre-eclampsia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T19%3A54%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20therapeutic%20effects%20of%20ergothioneine%20in%20pre-eclampsia&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Kerley,%20Robert%20N.&rft.date=2018-03&rft.volume=117&rft.spage=145&rft.epage=157&rft.pages=145-157&rft.issn=0891-5849&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2017.12.030&rft_dat=%3Cproquest_cross%3E1982841573%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c436t-4f2c0b25b7720bfbc9060b5597a398430fb2271cc7d978e0a77dc6fd8a250dbb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1982841573&rft_id=info:pmid/29284116&rfr_iscdi=true |